Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study.


Journal

Clinical oral investigations
ISSN: 1436-3771
Titre abrégé: Clin Oral Investig
Pays: Germany
ID NLM: 9707115

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 26 07 2018
accepted: 11 01 2019
pubmed: 24 1 2019
medline: 18 12 2019
entrez: 24 1 2019
Statut: ppublish

Résumé

The aim of this study was to investigate the predictive value of the biomarkers FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas. Immunohistochemical staining of FHIT, p27, and pERK1/ERK2 of 265 patients with salivary gland carcinomas was conducted, and associations with clinico-histopathological data, overall survival, and disease-specific survival were examined. Expression of FHIT (quick score 98.7 vs. 206.4) and p27 (QS 187.3 vs. 244.8) was significantly lower in carcinomas compared to non-tumor control tissue. Loss of FHIT frequently occurred in ACC (55.2%), SDC (68.2%), and SCC (100%). In the totality of tumors, loss of FHIT expression was found in 46.7% (106/227) and was significantly associated with advanced T stage and UICC stage, high-grade histology, loss of p27, PI3K, and survivin. FHIT positivity went along with significantly better overall and disease-specific survival. Negativity of p27 occurred in 28.7% (70/244) of tumors, particularly in SDC (54.4%) and SCC (50%). In the totality of tumors, p27 was associated with advanced patient age, high-grade histology, PI3K, survivin as well as better overall and disease-specific survival (p < 0.05). Positive pERK1/ERK2 expression correlated with positive survivin expression but did not affect overall survival in the totality of tumors. In mucoepidermoid carcinomas, pERK1/ERK2 expression was associated with low-grade malignancy, positive nuclear survivin, and better disease-specific survival. Loss of FHIT and p27 characterizes aggressive tumor growth and unfavorable prognosis in salivary gland cancer. The results may help to stratify patient-specific therapies according to individual tumor characteristics.

Identifiants

pubmed: 30673867
doi: 10.1007/s00784-019-02809-z
pii: 10.1007/s00784-019-02809-z
doi:

Substances chimiques

CDKN1B protein, human 0
Neoplasm Proteins 0
fragile histidine triad protein 0
Cyclin-Dependent Kinase Inhibitor p27 147604-94-2
MAPK1 protein, human EC 2.7.11.24
MAPK3 protein, human EC 2.7.11.24
Mitogen-Activated Protein Kinase 1 EC 2.7.11.24
Mitogen-Activated Protein Kinase 3 EC 2.7.11.24
Acid Anhydride Hydrolases EC 3.6.-

Types de publication

Journal Article

Langues

eng

Pagination

3801-3809

Références

J Cancer. 2016 Jan 10;7(3):314-23
pubmed: 26918045
Am J Pathol. 2003 Sep;163(3):957-67
pubmed: 12937136
Curr Treat Options Oncol. 2017 Jul;18(7):43
pubmed: 28639231
Mod Pathol. 2002 Dec;15(12):1366-73
pubmed: 12481019
Br J Cancer. 2005 Jun 20;92(12):2206-15
pubmed: 15928662
Oral Dis. 2002 Sep;8(5):229-40
pubmed: 12363107
J Clin Oncol. 2009 Dec 10;27(35):5924-30
pubmed: 19884556
Oral Oncol. 2012 Sep;48(9):822-30
pubmed: 22445095
Oral Oncol. 2010 Mar;46(3):195-9
pubmed: 20060354
J Biol Chem. 2001 Nov 2;276(44):40888-95
pubmed: 11527971
Biochem Biophys Res Commun. 2010 Apr 30;395(2):219-24
pubmed: 20361940
Oral Oncol. 2006 Nov;42(10):1005-10
pubmed: 16757206
Br J Cancer. 2010 Aug 10;103(4):510-6
pubmed: 20664595
Cancer Res. 2001 Jun 15;61(12):4827-36
pubmed: 11406559
Surg Oncol. 2006 Aug;15(2):97-106
pubmed: 17123889
Surg Oncol. 2006 Dec;15(4):223-33
pubmed: 17382535
Hum Pathol. 2012 Jun;43(6):921-31
pubmed: 22154363
Br J Cancer. 2012 Feb 14;106(4):719-26
pubmed: 22240798
Cancer Res. 2014 Jan 15;74(2):412-9
pubmed: 24408923
Virchows Arch. 2013 Jan;462(1):65-72
pubmed: 23242174
Cancer Immunol Immunother. 2009 Mar;58(3):469-73
pubmed: 18663445
Mod Pathol. 2001 Oct;14(10):1008-14
pubmed: 11598171
Hum Pathol. 2008 Jan;39(1):126-36
pubmed: 17949785
Lancet Oncol. 2002 Dec;3(12):748-54
pubmed: 12473516
ScientificWorldJournal. 2014 Mar 16;2014:179698
pubmed: 24757411
Int J Cancer. 2005 Apr 20;114(4):509-12
pubmed: 15578717
Cancer. 2014 Nov 15;120(22):3446-56
pubmed: 24948110
Histopathology. 2008 Nov;53(5):567-77
pubmed: 18983466
Oncogene. 2006 May 11;25(20):2860-72
pubmed: 16407838
Nat Rev Cancer. 2008 Apr;8(4):253-67
pubmed: 18354415

Auteurs

Mathias Fiedler (M)

Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Patty Renner (P)

Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Jürgen Schubert (J)

, Neckarstr.16, 95445, Bayreuth, Germany.

Florian Weber (F)

Department of Pathology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Arndt Hartmann (A)

Institute of Pathology, University Hospital of Erlangen, Krankenhausstraße 8/10, 91054, Erlangen, Germany.

Heinrich Iro (H)

Department of Otorhinolaryngology and Head and Neck Surgery, University of Erlangen-Nuremberg, Waldstraße 1, 91054, Erlangen, Germany.

Veronika Vielsmeier (V)

Department of Otorhinolaryngology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Christopher Bohr (C)

Department of Otorhinolaryngology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Michael Gerken (M)

Center of Tumor Registry, University of Regensburg, Am BioPark 9, 93053, Regensburg, Germany.

Torsten E Reichert (TE)

Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Tobias Ettl (T)

Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. tobias.ettl@ukr.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH